

Test Report EN 14675:2015 Chemical disinfectants and antiseptics – Quantitative suspension test for the evaluation of virucidal activity of chemical disinfectants and antiseptics used in the veterinary area- Test method and requirements (Phase 2/Step 1)

Test Laboratory BluTest Laboratories Ltd

5 Robroyston Oval, Nova Business Park, Glasgow, G33 1AP

Identification of sample

Name of the product Safe4 Disinfectant Cleaner

Batch number 3060

Client Safe Solutions (Safe4) Limited

Client Address Bostock Road, Wharton Green, Winsford, CW7 3BD

Project Code BT-SAF-19

Date of Delivery 02 September 2019

Storage conditions Ambient

Active substances Benzyl Alkyldimethyl chloride, polyhexamethylene biguanide

hydrochloric acid

Test Method and its validation

Method 1 part interfering substance + 1 part virus suspension + 8 parts

biocide were mixed and incubated at the indicated contact temperature for the indicated contact times. Assays were validated by a cytotoxicity control, interference control, neutralisation control and a formaldehyde internal standard.

Neutralisation Dilution-neutralisation/Enhanced neutralisation gel filtration

Eagles minimum essential medium + 5% v/v foetal bovine serum

at 4°C

Experimental Conditions

Period of analysis 17 September 2019 to 22 September 2019

Product diluents used Sterile, synthetic hard water

Product test concentrations 1:10; 1:50; 1:500

Appearance product dilutions

Appearance in test mixture

No changes noted- stable

No changes noted- stable

Contact times (minutes) $5 \pm 10s$ Test temperature $10^{\circ}\text{C} \pm 1^{\circ}\text{C}$

Interfering substances 3.0 g/l bovine albumin Temperature of incubation $37^{\circ}\text{C} + 1^{\circ}\text{C} + 5\% \text{ CO}_2$

Identification of virus Vaccinia virus Elstree Strain VR-1549/ VERO Cells



PROTOCOL SUMMARY

The basic virucidal efficacy test is set up with three concentrations of disinfectant and a 5-minute contact time. Virus is exposed to disinfectant in 24-well plates, then neutralised, serially diluted and virus titred in 96-well tissue culture plates to determine the tissue culture infectious dose₅₀ (TCID₅₀) of surviving virus. Vaccinia virus Elstree Strain VR-1549/ VERO Cells are assayed in parallel in each test. TCID₅₀ is determined by the method of Karber¹.

Cytotoxicity control

The neutralised disinfectant is measured for its effects on the host cells used to propagate the virus, to determine the sensitivity of the assay.

Interference control

The end point titration of the virus is exposed to three different sub-lethal concentrations of neutralised disinfectant to measure the effect of sub-lethal concentrations of disinfectant on virus infectivity in relation to the titre achieved on untreated cells.

Disinfectant suppression control

Virus is added to the highest concentration of disinfectant and then the mixture immediately removed and neutralised. The neutralised virus titre is then determined to assess the efficiency of the neutralisation procedure.

Virus recovery control

Virus titre is determined for virus in contact with sterile hard water at t=0, t=5 and at t=60. The virus titre after 5 minutes is then compared to the recovery of disinfectant-treated virus to measure the log reduction in virus titre. The virus titre at 60 minutes is compared to the reference virus inactivation control.

Reference virus inactivation control

Virus is exposed to 0.7% W/V formaldehyde and the recovery of virus determined by TCID₅₀ after 5, 15, 30 and 60 minutes, in order to assess that the test virus has retained reproducible biocide resistance. In addition, the formaldehyde cytotoxicity of neutralised formaldehyde is determined, to measure assay sensitivity.

1Kärber, G.: Beitrag zur Kollektiven Behandlung Pharmakologischer Reihenversuche. Arch. Exp. Path. Pharmak. 162 (1931): 480-487.



Vaccinia virus Elstree Strain VR-1549/ VERO Cells

SOP 10000 V02 EN14675 Suspension test results for the efficacy of Safe4 Disinfectant Cleaner, BT-SAF-19 from Safe Solutions (Safe4) Ltd against Vaccinia														
Virus Recovery 0 min		Virus Recovery 5 min		Cytotoxicity		Disinfectant Suppression		Exposure Time	1:500		1:50		1:10	
	· · · · · · · · · · · · · · · · · · ·				 									
raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml		raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml
5.17	4.68E+06	5.00	3.16E+06	0.00	3.16E+01	5.17	4.68E+06	t = 5 min	3.17	4.68E+04	0.00	3.16E+01	0.00	3.16E+01
	4.68E+06		3.16E+06		3.16E+01		4.68E+06			4.68E+04		3.16E+01		3.16E+01
	6.67		6.50		1.50		6.67	log		4.67		1.50		1.50
							0.00	log difference		1.83		5.00		5.00

Summary table of results of virucidal activity against Vaccinia under CLEAN conditions for Safe4 Disinfectant												
Cleaner, BT-SAF-19 from Safe Solutions (Safe4) Ltd												
Product:	Interfering substance	Concentration	Level of cytotoxicity		>4 lg reduction after 'X' Min							
				0 min	1 min	3 min	5 min	60 min				
Safe 4		1:10	1.50	n.a.	n.a.	n.a.	1.50	n.a.	<5 min			
Disinfectant	3.0g/I BSA	1:50	1.50	n.a.	n.a.	n.a.	1.50	n.a.	<5 min			
Cleaner		1:500	1.50	n.a.	n.a.	n.a.	4.67	n.a.	>5 min			
Virus Control	CLEAN	n.a.	n.a.	6.67	n.a.	n.a.	6.50	6.67	n.a.			
				0 min	5 min	15 min	30 min	60 min				
Formaldehyde	PBS	0.7% (w/v)	2.50	n.a.	5.50	4.50	3.50	3.50	>60 min			



Control Data

Stock Virus (TCID ₅₀)		6.33	6.76E+07												
Formaldehyde reference in		nactivation control													
Virus recovery 0 min		Virus recovery 60 min				Exposure time	0.7% Formaldehyde								
							5		15		30		60		
raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml		raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	
5.17	4.68E+06	5.17	4.68E+06	1.00	3.16E+02	60 min	4.00	3.16E+05	3.00	3.16E+04	2.00	3.16E+03	2.00	3.16E+03	
	4.68E+06		4.68E+06		3.16E+02			3.16E+05		3.16E+04		3.16E+03		3.16E+03	
	6.67		6.67		2.50	log		5.50		4.50		3.50		3.50	
						log difference		1.17		2.17		3.17		3.17	
No Column Co	ontrol				Interferen	ce control									
		Virus Recovery								Virus dilution					
		60 min raw data TCID ₅₀ /ml					interfer	ence control	-3	-4	-5	-6	-7	-8	
									1	1	1	0.67	0	0	
		5.17	4.68E+06				PB5	S Control	3.16E+02	3.16E+02	3.16E+02	1.48E+02	3.16E+01	3.16E+01	
		4.68E+06							2.50	2.50	2.50	2.17	1.50	1.50	
		6.67					1	1	1	0.83	0.5	0			
							P	roduct	3.16E+02	3.16E+02	3.16E+02	2.14E+02	1.00E+02	3.16E+01	
									2.50	2.50	2.50	2.33	2.00	1.50	
							Log Difference		0.00	0.00	0.00	-0.16	-0.50	0.00	
							Product Cyt Dilution		-1	-1	-1	-1	-1	-1	
							PBS Dilution		Neat	Neat	Neat	Neat	Neat	Neat	



CONCLUSION

Verification of the methodology

A test is only valid if the following criteria are fulfilled:

- a) Test virus suspension has at least a concentration which allows the determination of a 4 log₁₀ reduction of the virus titre.
- b) Detectable titre reduction is at least 4 log₁₀.
- c) Difference of the logarithmic titre of the virus control minus the logarithmic titre of the test virus in the reference inactivation test is between 0.5 and 2.5 after 30 min and between 2 and 4.5 after 60 min for virus.
- d) Cytotoxicity of the product solution does not affect cell morphology and growth or susceptibility for the test virus in the dilutions of the test mixtures which are necessary to demonstrate a 4 log₁₀ reduction of the virus.
- e) The interference control result does not show a difference of < 1.0 log₁₀ of virus titre in comparison to the virus recovery control; dilutions of disinfectant to sub-acute levels does not interfere in the generation of viral cytopathic effect.
- e) Neutralisation validation. This is called the disinfectant suppression test in this protocol. The disinfectant was neutralised by column chromatography through an Illustra Microspin S-400 HR column to achieve the best possible neutralisation available for this test. The difference for virus is not greater than 0.5 log₁₀ indicating effective neutralisation of the virucidal activity of the disinfectant by dilution at a concentration of 1:10.
- f) A difference of <0.5 log₁₀ should be observed between virus recovered directly from the virus recovery control at 60 minutes and virus from the same control recovered through an Illustra Microspin S-400 HR column

According to EN 14675:2015, Safe4 Disinfectant Cleaner POSSESSES VIRUCIDAL activity at a concentration of 1:50 as tested after 5 MINUTES at 10°C under CLEAN conditions (3.0 g/l bovine albumin) against Vaccinia virus Elstree Strain VR-1549/ VERO Cells that is a surrogate for ENVELOPED VIRUSES.

Signed

Dr Chris Woodall, Director BluTest Laboratories Ltd Glasgow, UK.

Date: 01 October 2019

DISCLAIMER

The results in this test report only pertain to the sample supplied.

BluTest (BT) has performed the testing detailed in this report using reasonable skill and care and has used reasonable endeavours to carry out the testing in accordance with an EN 14675 protocol. All forecasts, recommendations and results contained in this report are submitted in good faith. However, other than as expressly set out in this report, no warranty is given (i) in relation to the testing or the use(s) to which any results or deliverables produced in the course of the testing are or may be put by the Client or their fitness or suitability for any particular purpose or under any special conditions notwithstanding that any such purpose or conditions may have been made known to BT or (ii) that the intended results or deliverables from the testing can be achieved or (iii) that the Client can freely make use of the results or the deliverables without infringing any third party intellectual property rights and the Client will be deemed to have satisfied itself in this regard. BT shall have no liability (which is hereby excluded to the fullest extent permissible by law) in respect of any loss, liability or damage, including without limitation any indirect and/or consequential loss such as loss of profit or loss of business, market or goodwill, that the Client may suffer directly or indirectly as a result of or in connection with: (i) the performance of the testing; (ii) the use of any materials, samples or other information provided by the Client for use in the testing; and (iii) the Client's reliance upon or use of any results or deliverables provided as part of the testing.

Page **5** of **5**